Novo Nordisk stock plunged after CagriSema missed against Eli Lilly’s Zepbound, but new obesity drug data and a low valuation ...

In its second Blueprint for Change Programme business case, Novo Nordisk reports that its Triple Bottom Line business principle, balancing economic, social and environmental decisions, has created ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Danish pharmaceutical giant Novo Nordisk is under pressure as strong competition emerges for its weight-loss injection Wegovy and diabetes drug Ozempic. The company now expects lower sales in 2026 - ...

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered ...

Its newly earned indications could impact financial results in 2026. The drugmaker should also make decent pipeline progress. Novo Nordisk's shares look reasonably valued. 10 stocks we like better ...